Drugs / AUTO4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03590574 | Aug 2018 → Dec 2024 | anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified | Autolus Limited | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AUTO4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03590574 ↗ |
| Modality | Cell therapy | “TRBC1-directed autologous chimeric antigen receptor (CAR) T cells (AUTO4)” PMID 39528665 ↗ Nov 2024 |
| Route | Intravenous | “the patient will receive AUTO4 intravenously as a single dose” NCT03590574 ↗ |
| Target | TRBC1 | “CAR T cell treatment targeting TRBC1” NCT03590574 ↗ |